Thank you for subscribing!
Wise-Owl Aug 15, 2023
Our micro-cap cannabis and life sciences Investment Bod Science (ASX:BOD) has clinical trial results incoming. In less than two weeks we should know the results from the Phase IIb clinical trial for insomnia.
Next Investors Oct 25, 2021
Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.
Finfeed Archived May 21, 2021
Creso Pharma (ASX: CPH) will enter the Polish animal health market after signing a Letter of Intent with Polvet Healthcare Teodorowski Spółka Jawna. It has also finalised the development of anibidiol® swine, a new and innovative hemp flour and oat bran based complementary feed product.
Finfeed Archived Apr 12, 2021
Cannabis centric healthcare company Bod Australia Limited (ASX: BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 06, 2021
Creso Pharma (ASX: CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN.
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
Finfeed Archived Mar 19, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has announced three new purchase orders for its wholly-owned Canadian subsidiary, Mernova Medicinal Inc, with a total value of C$177,122.40 (A$183,019.55).
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
Next Investors Mar 01, 2021
Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.
Finfeed Archived Feb 17, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has announced that its wholly-owned Canadian subsidiary Mernova Medicinal Inc. has secured four purchase orders (“PO”) for its leading Ritual Green product range, with a total value of C$494,131 (A$502,199).
Finfeed Archived Feb 03, 2021
Investors who took a stake in Creso Pharma (ASX:CPH) three months ago are now looking at a near ten-bagger, with more upside to come.
Next Investors Jan 19, 2021
Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.
Finfeed Archived Dec 21, 2020
Creso Pharma Limited (ASX: CPH, FRA: 1X8) has secured regulatory approval from the Ministry of Agriculture and Animal Feed in Uruguay (Ministerio de Ganadaria, Agricultura y Pesca) through its commercial partner Adler Laboratories, Uruguay for its line of animal health products, anibidiol®.
Finfeed Archived Dec 11, 2020
Roots Sustainable Agricultural Technologies Limited (ASX: ROO) has secured a Non-binding Letter of Intent (LOI) with smart technology provider, Humboldt CCTV to integrate its proprietary Root Zone Temperature Optimisation (RZTO) technology and revolutionary heat exchange stub product into Humboldt’s Smart Agriculture solution.
Catalyst Hunter Dec 07, 2020
Creso Pharma Limited (ASX: CPH) has substantial operations in North America and the US decision to legalise cannabis paves the way for the company to enter into the world’s largest recreational and medical cannabis market.
Finfeed Archived Dec 07, 2020
Creso Pharma Limited (ASX: CPH; FRA: 1X8) has advised that the US House of Representatives has passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis for the US Controlled Substances Act.
Next Investors Dec 02, 2020
Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.
Finfeed Archived Oct 27, 2020
Through its Mernova subsidiary, Creso Pharma (ASX: CPH) has delivered its third purchase order (PO) from the Nova Scotia Liquor Corp
Join Our Mailing List
